Histogen
Histogen
HSTO
OTC
0.03
USD
0.00%
About
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096.
It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases.
Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 350 |
| Three Month Average Volume | 27.3K |
| High Low | |
| Fifty-Two Week High | 0.93 USD |
| Fifty-Two Week Low | 0.0501 USD |
| Fifty-Two Week High Date | 12 Oct 2023 |
| Fifty-Two Week Low Date | 19 Apr 2024 |
| Price and Volume | |
| Current Price | 0.2225 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -4.27% |
| Thirteen Week Relative Price Change | 20.87% |
| Twenty-Six Week Relative Price Change | -35.76% |
| Fifty-Two Week Relative Price Change | -73.73% |
| Year-to-Date Relative Price Change | -38.94% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | 29.36% |
| Twenty-Six Week Price Change | -29.37% |
| Five Day Price Change | 1.14% |
| Fifty-Two Week Price Change | -67.09% |
| Year-to-Date Price Change | -27.69% |
| Month-to-Date Price Change | 1.14% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.37215 USD |
| Book Value Per Share (Most Recent Quarter) | 1.27254 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 3.37215 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.27254 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.78781 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.17373 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00444 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -3.45952 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.89551 USD |
| Normalized (Last Fiscal Year) | -3.45952 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -3.45952 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.89551 USD |
| Including Extraordinary Items (Last Fiscal Year) | -3.45952 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.89551 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.83466 USD |
| Cash Per Share (Most Recent Quarter) | 1.07052 USD |
| Cash Flow Per Share (Last Fiscal Year) | -3.42308 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.86455 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.3569 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -141 |
| Cash Flow Revenue (Trailing Twelve Months) | -53,026 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -65,173.68% |
| Pretax Margin (Last Fiscal Year) | -282.41% |
| Pretax Margin (5 Year) | -126.17% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 100.00% |
| Gross Margin (Trailing Twelve Months) | 21.05% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -282.38% |
| Operating Margin (Trailing Twelve Months) | -63,442.11% |
| Operating Margin (5 Year) | -128.24% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -282.41% |
| Net Profit Margin (Trailing Twelve Months) | -65,173.68% |
| Net Profit Margin (5 Year) | -126.17% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -55.18% |
| Tangible Book Value (5 Year) | -12.44% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 0.00% |
| Revenue Growth (3 Year) | -36.10% |
| Revenue Change (Trailing Twelve Months) | -99.50% |
| Revenue Per Share Growth | -65.71% |
| Revenue Growth (5 Year) | -30.96% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 53.30% |
| Total Debt (5 Year) | -74.57% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 10.89% |
| EPS Change (Trailing Twelve Months) | 32.61% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 0 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -4,573,000 |
| Net Debt (Last Fiscal Year) | -12,095,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 0 |
| Price to Sales (Trailing Twelve Months) | 50 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 14 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 14 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 11 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -9,899,000 |
| Free Cash Flow (Trailing Twelve Months) | -10,075,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -10,643 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -45.96% |
| Return on Assets (Trailing Twelve Months) | -88.44% |
| Return on Assets (5 Year) | -45.31% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -62.42% |
| Return on Equity (Trailing Twelve Months) | -108.97% |
| Return on Equity (5 Year) | -162.15% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -47.53% |
| Return on Investment (Trailing Twelve Months) | -90.66% |
| Return on Investment (5 Year) | -60.53% |